| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ozenoxacin |
| Brand | Dubine® |
| Indication | For the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older. |
| Assessment Process | |
| Rapid review commissioned | 12/11/2018 |
| Rapid review completed | 13/12/2018 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
